✦ LIBER ✦

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

✍ Scribed by Wolff, A. C.; Lazar, A. A.; Bondarenko, I.; Garin, A. M.; Brincat, S.; Chow, L.; Sun, Y.; Neskovic-Konstantinovic, Z.; Guimaraes, R. C.; Fumoleau, P.; Chan, A.; Hachemi, S.; Strahs, A.; Cincotta, M.; Berkenblit, A.; Krygowski, M.; Kang, L. L.; Moore, L.; Hayes, D. F.

Book ID: 118235609
Publisher: American Society of Clinical Oncology
Year: 2013
Tongue: English
Weight: 194 KB
Volume: 31
Category: Article
ISSN: 0732-183X
DOI: 10.1200/jco.2011.38.3331

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized phase III trial of paclitax

A randomized phase III trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: Eastern cooperative oncology group trial E2100

✍ R. Zon; Miller; M. Wang; J. Gralow; M. Dickler; M. Cobleigh; E. Perez; T. Shenki 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 129 KB

2098 ORAL BCIRG 007: First overall survi

2098 ORAL BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)

✍ T. Pienkowski; M. Pegram; J. Forbes; V. Valero; W. Eiermann; G. Von Minckwitz; M 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 77 KB

Randomized phase III trial of trastuzuma

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

✍ Kenichi Inoue; Kazuhiko Nakagami; Mitsuhiro Mizutani; Yasuo Hozumi; Yasuhiro Fuj 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 368 KB

First results of a randomized phase III

First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) — EORTC 10951 in collaboration with the exemestane working group and NCIC Clinical Trials Group

✍ R Paridaens; P Therasse; L Dirix; L Beex; M.J Piccart; D Cameron; T Cufer; K Roo 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 172 KB

Anastrozole (‘Arimidex’) versus tamoxife

Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial

✍ Beat Thürlimann; Dagmar Hess; Dieter Köberle; Isabella Senn; Pierluigi Ballabeni 📂 Article 📅 2004 🏛 Springer US 🌐 English ⚖ 348 KB